Skip to main content

APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease.

Publication ,  Journal Article
Datta, S; Antonio, BM; Zahler, NH; Theile, JW; Krafte, D; Zhang, H; Rosenberg, PB; Chaves, AB; Muoio, DM; Zhang, G; Silas, D; Li, G; Bain, JR ...
Published in: The Journal of clinical investigation
January 2024

Two coding variants of apolipoprotein L1 (APOL1), called G1 and G2, explain much of the excess risk of kidney disease in African Americans. While various cytotoxic phenotypes have been reported in experimental models, the proximal mechanism by which G1 and G2 cause kidney disease is poorly understood. Here, we leveraged 3 experimental models and a recently reported small molecule blocker of APOL1 protein, VX-147, to identify the upstream mechanism of G1-induced cytotoxicity. In HEK293 cells, we demonstrated that G1-mediated Na+ import/K+ efflux triggered activation of GPCR/IP3-mediated calcium release from the ER, impaired mitochondrial ATP production, and impaired translation, which were all reversed by VX-147. In human urine-derived podocyte-like epithelial cells (HUPECs), we demonstrated that G1 caused cytotoxicity that was again reversible by VX-147. Finally, in podocytes isolated from APOL1 G1 transgenic mice, we showed that IFN-γ-mediated induction of G1 caused K+ efflux, activation of GPCR/IP3 signaling, and inhibition of translation, podocyte injury, and proteinuria, all reversed by VX-147. Together, these results establish APOL1-mediated Na+/K+ transport as the proximal driver of APOL1-mediated kidney disease.

Duke Scholars

Published In

The Journal of clinical investigation

DOI

EISSN

1558-8238

ISSN

0021-9738

Publication Date

January 2024

Volume

134

Issue

5

Start / End Page

e172262

Related Subject Headings

  • Mice, Transgenic
  • Mice
  • Kidney Diseases
  • Immunology
  • Humans
  • HEK293 Cells
  • Genetic Variation
  • Apolipoprotein L1
  • Animals
  • 42 Health sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Datta, S., Antonio, B. M., Zahler, N. H., Theile, J. W., Krafte, D., Zhang, H., … Olabisi, O. A. (2024). APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease. The Journal of Clinical Investigation, 134(5), e172262. https://doi.org/10.1172/jci172262
Datta, Somenath, Brett M. Antonio, Nathan H. Zahler, Jonathan W. Theile, Doug Krafte, Hengtao Zhang, Paul B. Rosenberg, et al. “APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease.The Journal of Clinical Investigation 134, no. 5 (January 2024): e172262. https://doi.org/10.1172/jci172262.
Datta S, Antonio BM, Zahler NH, Theile JW, Krafte D, Zhang H, et al. APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease. The Journal of clinical investigation. 2024 Jan;134(5):e172262.
Datta, Somenath, et al. “APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease.The Journal of Clinical Investigation, vol. 134, no. 5, Jan. 2024, p. e172262. Epmc, doi:10.1172/jci172262.
Datta S, Antonio BM, Zahler NH, Theile JW, Krafte D, Zhang H, Rosenberg PB, Chaves AB, Muoio DM, Zhang G, Silas D, Li G, Soldano K, Nystrom S, Ferreira D, Miller SE, Bain JR, Muehlbauer MJ, Ilkayeva O, Becker TC, Hohmeier H-E, Newgard CB, Olabisi OA. APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease. The Journal of clinical investigation. 2024 Jan;134(5):e172262.

Published In

The Journal of clinical investigation

DOI

EISSN

1558-8238

ISSN

0021-9738

Publication Date

January 2024

Volume

134

Issue

5

Start / End Page

e172262

Related Subject Headings

  • Mice, Transgenic
  • Mice
  • Kidney Diseases
  • Immunology
  • Humans
  • HEK293 Cells
  • Genetic Variation
  • Apolipoprotein L1
  • Animals
  • 42 Health sciences